CRISPR NEWS

Doudna-Charpentier team files its U.S. Court of Appeals for the Federal Circuit reply brief

In this brief, the Doudna-Charpentier team reiterates the position taken in its Appellant Brief (see Doudna-Charpentier team submits Appellant Brief to U.S. Court of Appeals for the Federal Circuit), which states that the Patent Trial and Appeal Board (PTAB) decision was made in error and did not consider relevant evidence.

 

Download the Doudna-Charpentier reply brief

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issues 9th and 10th CRISPR patents to CVC July 23, 2019
U.S. Patent and Trademark Office issues 8th CRISPR patent to CVC July 16, 2019
U.S. Patent and Trademark Office issues 7th CRISPR patent to CVC July 2, 2019
Read moreArrow-down